Replacement renal therapy in the treatment of patients with a severe course of the new coronavirus infection

Objective: to study the use of RRT methods and their influence on the results of treatment of patients with severe COVID-19.

Subjects and methods. We retrospectively analyzed the data of 283 patients with COVID-19 in the intensive care units of Moscow City Hospital no. 40 in 2020 who had received RRT as one of the treatment methods.

Results. Frequency of RRT in COVID-19 patients in ICU of Moscow City Hospital no. 40 for 2020 made 5.7% (504 out of 8.711 patients treated in ICU received RRT). In 86% of cases, RRT was performed for renal indications. At the time of initiation of RRT, the studied groups did not differ according to SOFA score. The frequency of using dialysis units with high and low cut-off point in the groups of survived and deceased patients differed significantly. The surgery itself started at relatively the same time from the onset and statistically significantly earlier in the group of survivors from the beginning of tracheal intubation (4.9 ± 0.5 vs 6.8 ± 0.3 days, p = 0.0013). Against the background of ongoing therapy, overall severity of the state progressed in the group of deceased patients to 9.9 ± 0.2 SOFA scores, while in the group of survivors there was an improvement to 6.1 ± 0.4 scores.

1. Sokolov А.А. Sokolov D.V., Pevzner D.V. et al. Extracorporeal blood purification in the complex treatment of the novel coronavirus infection: opportunities review. Messenger of Anesthesiology and Resuscitation, 2020, vol. 17, no. 4, pp. 31-40. (In Russ.) http://doi.org/10.21292/2078-5658-2020-17-4-31-40.

2. Alberici F., Delbarba Е., Manenti C. et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int. Rep., 2020, vol. 5, pp. 580–585. doi: 10.1016/j.ekir.2020.04.001.

3. Ceribelli A., Motta F., de Santis M. et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J. Autoimmun., 2020, vol. 109, PMID: 32253068. doi: 10.1016/j.jaut.2020.102442.

4. Chen X., Zhao B., Qu Y. et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis., 2020, pp. 449.

5. Colafrancesco S., Alessandri С., Conti F. et al. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun. Rev., 2020, vol. 19, no. 7. PMID: 32387470 doi: 10.1016/j.autrev.2020.102573.

6. Dastan F., Saffaei A., Mortazavi S.M. et al. Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: a promising option for severe COVID-19. J. Glob. Antimicrob. Resist., 2020, vol. 21, pp. 340‒341.

7. Deng F., Zhang L., Lyu L. et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med. Clin. (Barc), 2020, vol. 156, no. 7, pp. 324‒331. doi: 10.1016/j.medcli.2020.11.030.

8. Doher M.P., de Carvalho F.R.T., Scherer P.F. et al. Acute kidney injury and renal replacement therapy in critically ill COVID-19 patients: risk factors and outcomes: a single-center experience in Brazil. Blood Purif., 2020, vol. 18, pp. 1–11. doi:10.1159/000513425.

9. Eberhardt K.A., Schwickerath С.M., Heger E. et al. Aemia corresponds to disease severity and antibody response in hospitalized COVID-19 patients. Viruses, 2020, vol. 12, no. 9, pp. 1045. doi: 10.3390/v12091045.

10. Grifoni E., Valoriani A., Cei F. et al. Interleukin-6 as prognosticator in patients with COVID-19. J. Infect., 2020, vol. 81, no. 3, pp. 452‒482. doi: 10.1016/j.jinf.2020.06.008. Epub 2020 Jun. 8.

11. Hedrick T.L. et al. COVID-19: Clean up on IL-6. Am. J. Respir. Cell. Mol. Biol., 2020, vol. 63, no. 4, pp. 541‒543. doi: 10.1165/rcmb.2020-0277LE.

12. Henry B.M., Murray B.P., Hagan R.S. et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med., 2020, vol. 58, no. 7, pp. 1021‒1028. PMID: 32286245 DOI: 10.1515/cclm-2020-0369.

13. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, no. 10223, pp. 497–506. doi: https://doi.org/10.1016/S0140-6736(20)30183-5.

14. Ji P., Zhu J., Zhong Z., et al. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Medicine (Baltimore), 2020, vol. 99, no. 47, pp. e23315. Published online 2020 Nov. 20. doi: 10.1097/MD.0000000000023315 PMCID: PMC7676531 PMID: 33217868.

15. Karkar A., Ronco C. Prescription of CRRT: a pathway to optimize therapy. PMID: 32144519. PMCID: PMC7060300. doi: 10.1186/s13613-020-0648-y.